Dihydroxypropyl cysteine peptide and agent containing this...

Details Dihydroxypropyl cysteine peptide and agent containing this... Dihydroxypropyl cysteine peptide and agent containing this...

2003-03-10

2008-10-14

Navarro, Mark (Department: 1645)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

11 to 14 amino acid residues in defined sequence

C530S300000, C514S014800, C514S016700, C514S669000, C514S667000, C514S772300, C424S486000, C424S180100, C424S182100

Reexamination Certificate

active

07435790

ABSTRACT:
The invention relates to a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids bonded in the form of esters at the dihydroxypropyl group, and which has the following sequence:DhcGN NDE SNI SFK EK.The invention relates also to a composition comprising the mentioned peptide.

REFERENCES:
patent: 3950542 (1976-04-01), Kalopissis et al.
patent: 5179079 (1993-01-01), Hansen et al.
patent: 5214062 (1993-05-01), Mark et al.
patent: 5358933 (1994-10-01), Porro
patent: 5788962 (1998-08-01), Wise et al.
patent: 5856444 (1999-01-01), Kawakita et al.
patent: 6376203 (2002-04-01), Matsuda et al.
patent: 6506892 (2003-01-01), Webb et al.
patent: 6573242 (2003-06-01), Muehlradt
patent: 2002/0155117 (2002-10-01), Suciu-Foca
patent: 2004/0127405 (2004-07-01), Muhlradt et al.
patent: 2004/0249133 (2004-12-01), Muhlradt et al.
patent: 2005/0192217 (2005-09-01), Muhlradt et al.
patent: 2005/0276813 (2005-12-01), Muhlradt et al.
patent: 2006/0134061 (2006-06-01), Muhlradt et al.
patent: 2007/0203185 (2007-08-01), Muhlradt et al.
patent: 96/16987 (1996-06-01), None
patent: 98/27110 (1998-06-01), None
patent: 99/59610 (1999-11-01), None
Swiss-Prot accession No. P94932, Monocytic differentiation/activation factor, name P48.
Hall, Robert H et al, Biochem. J., vol. 319, pp. 919-927, 1996, cDNA and genomic cloning and expression of the P48 monocytic differentiation/activation factor, aMycoplasma fermentansgene product.
Muhlradt, Peter F. et al, J. Exp. Med. vol. 185, No. 22. Jun. 2, 1997, pp. 1951-1958, Isolation, structure elucidation and synthesis of a macrophage stimulatory lipopeptide fromMycoplasma fermentansacting at picomolar concentrations.
Chambaud, I et al, Trends in Microbiology, vol. 7, No. 12, Dec. 1999, pp. 493-499, Interactions beween mycoplasma lipoproteins and the host immune system.
Calcutt, M.J. et al, Infection and Immunity, Feb. 1999, vol. 67(2), pp. 760-771, Differential Posttranslational processing confers intraspecies variation of a major surface lipoprotein and a macrophage-activating lipopeptide ofMycoplasma fermentans.
Galanos, C et al, Journal of Endotoxin Research, vol. 6(6), pp. 471-476, MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monoply?.
Wise, K.S. et al, Infection and Immunity, vol. 61(8), pp. 3327-3333, Aug. 1993, A Family of strain-variant lipoproteins ofMycoplasma fermentans.
Bessler, WG et al, The Journal of Immunology, vol. 139(3), Sep. 1985, pp. 1900-1905.
Kostyal, DA et al, Infection and Immunity, Sep. 1994, vol. 62(9), pp. 3793-3800.
Muhlradt, PF et al, Infection and Immunity, vol. 59(11), pp. 3969-3974, Nov. 1991.
Muhlradt, PF et al, Infection and Immunity, vol. 62(9), pp. 3801-3807, Sep. 1994.
Muhlradt, PF e tal, Biochemistry, vol. 35, pp. 7781-7786, 1996.
Quentmeier, H et al, Infection and Immunity, May 1990, vol. 58(5), pp. 1273-1280.
Boslego, JW et al, Chapter 17, pp. 211-223, in Vaccines and Immunotherapy, 1991.
Ellis, Ronald W, Chapter 29, New technologies for making vaccines, pp. 568-575, in Vaccines, WB Saunders Company, 1988.
Hall et al (1996) reference of record.
Matsumoto, M et al, J. Exp. Med. , vol. 181, Jan. 1995, pp. 115-123.
Matsumoto, M et al, The Journal of Biological Chemistry, vol 273(20), May 15, 1998, pp. 12407-12414, Structural and functional properties of Complement activating Protein M161Ag, aMycoplasma fermentansGene product that induces cytokine production by Human Monocytes.
Jacobson, RM et al, Vaccine, vol. 19(2001), pp. 2438-2433, Adverse events and vaccination—the lack of power and predictability of infrequent events in pre-licensure study.
Leece, JG et al, Can. J. Comp. Med., pp. 90-93, vol. 43, Jan. 1979.
Lacombe, K et al, Vaccine, 2004, vol. 23, pp. 623-628.
Graham, BS et al, JID, 2005, vol. 191, Mar. 1, 2005, pp. 647-649.
Dazzi, F et al, Clinical Immunology and Immunopathology, vol. 75(1), Apr. 1995, pp. 26-32.
Chambaud, Isabelle et al, Treands in Microbiology, vol. 7(12), 1999, pp. 493499.
Uniprot Accession No. P94932, previously made for record.
Hall, Robert E et al, Biochem. J, 1996, vol. 319, pp. 919-927, cDNA and genomic cloning and expression of the P48 monocytic differentiation/ activation factor, aMycoplasma fermentansgene product.
Morr, Michael et al, Eur. J. Immunol., 2002, vol. 32, pp. 3337-3347, Differential recognition of structural details of bacterial lipopeptides by toll-like receptors.
Muhlradt, Peter F. et al, J. Exp. Med. vol. 185(11) Jun. 2, 1997.
Muhlradt, Peter F et al, Biochemistry, 1996, vol. 35, pp. 7781-7786.
Muhlradt, Peter F. et al, Infection and Immunity, Oct. 1998, vol. 66(10), pp. 4804-4810.
Hall, Robert E. et al, Microbial Pathogenesis, 1999, vol. 27, pp. 145-153, Expression of the monocytic differentiation activation factor P48 inMyoplasmaspecies.
Hall, Robert E. et al, Biochemical and Biophysical REsearch Communications, vol. 269, pp. 284-289, 2000, Induction of Leukemia Cell Differnetiation and Apoptosis by Recombinant P48, a Modulin Derived fromMyocplasma fermentans.
Seya, Tsukasa et al, The International Journal of Biochemistry and Cell Biology, vol. 34, pp. 901-906, 2002, Molecules in Focus, A Lipoprotein family fromMyocplasm fermentansconfers host immune activation through Toll-like receptor 2.
Rosati, Sergio et al, Infecion and Immunity, vol. 67(11), pp. 6213-6216, Nov. 1999, P48 Major Surface Antigen ofMycoplasma agalactiaeis homologous to a malp product ofMyocplasma fermentansand belongs to a Selected Family of Bacterial LIpoproteins.
Hall et al (reference of record).
Chambaud et al (reference of record).

Affiliated with

Also associated with

Rating

Dihydroxypropyl cysteine peptide and agent containing this... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dihydroxypropyl cysteine peptide and agent containing this..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydroxypropyl cysteine peptide and agent containing this... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4006360